GlassScriptPhysician profile
Anika Wilson
NPI 1306055330
$15,258.21
in general payments reported to CMS, 2019-2025
32 companies · $2,492 in 2025
The $2,492 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,398 · 2020: $650 · 2021: $1,321 · 2022: $1,549 · 2023: $3,798 · 2024: $3,051 · 2025: $2,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,340.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,065.95 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $2,016.47 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,590.54 | 2021-2025 | Caplyta |
| Corium, LLC | $1,165.41 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $869.71 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tris Pharma INC | $774.83 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $743.36 | 2019-2024 | Jornay Pm |
| Alkermes, INC. | $629.99 | 2019-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $571.06 | 2022-2025 | Auvelity |
| Neos Therapeutics, LP | $523.61 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Sunovion Pharmaceuticals INC. | $475.15 | 2019-2021 | |
| Lundbeck LLC | $467.65 | 2019-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $431.98 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $418.42 | 2019-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $270.18 | 2019-2025 | Fanapt |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $238.40 | 2019-2025 | Neurostar Tms Therapy System |
| Allergan, INC. | $199.17 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $178.17 | 2023-2025 | Quviviq, Quviviq |
| Adlon Therapeutics L.P. | $160.68 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $93.70 | 2022-2024 | Uzedy |
| Jazz Pharmaceuticals INC. | $70.52 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $59.13 | 2019-2025 | Relexxii |
| Arbor Pharmaceuticals, INC. | $38.64 | 2019 | |
| Bausch Health US, LLC | $31.67 | 2023-2025 | Aplenzin |
| Shire North American Group INC | $28.09 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $27.89 | 2019 | |
| Sage Therapeutics, LLC | $22.81 | 2025 | Zurzuvae |
| Noven Therapeutics, LLC | $21.39 | 2024 | Xelstrym |
| Noven Pharmaceuticals, INC. | $21.13 | 2024 | Xelstrym |
| Alfasigma USA, INC. | $19.22 | 2022 | |
| Novo Nordisk INC | $18.51 | 2024 | Ozempic |
| Almatica Pharma LLC | $14.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anika Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.